CD
LCTX icon

Chapin Davis’s Lineage Cell Therapeutics LCTX Stock Holding History

Chapin Davis’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.2K Hold
20,029
– – ﹤0.01% 256
2026
Q1 		$31.6K Hold
20,029
– – 0.01% 261
2025
Q4 		$33.4K Hold
20,029
– – 0.01% 244
2025
Q3 		$33.8K Hold
20,029
– – 0.01% 246
2025
Q2 		$18.2K Hold
20,029
– – 0.01% 230
2025
Q1 		$9.04K Buy
+20,029
New +$11.7K ﹤0.01% 224

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Chapin Davis's LCTX Position: Q2 2026 in Review

Chapin Davis held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 20,029 shares worth $26.2K. The position accounts for ﹤0.01% of the portfolio, ranked #256.

Chapin Davis first reported a position in LCTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $33.8K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Chapin Davis held 20,029 shares of Lineage Cell Therapeutics worth $26.2K as of Q2 2026.
  • Chapin Davis left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Chapin Davis's portfolio in Q2 2026, its #256 holding.
  • Chapin Davis first reported a position in Lineage Cell Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Chapin Davis's Lineage Cell Therapeutics position peaked at $33.8K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Chapin Davis's 13F filing for Q2 2026, filed 7 Jul 2026.